이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Galecto 관리

관리 기준 확인 3/4

Galecto's CEO는 Hans Schambye, Jan2020 에 임명되었습니다 의 임기는 4.42 년입니다. 총 연간 보상은 $ 965.12K, 52.4% 로 구성됩니다. 52.4% 급여 및 47.6% 보너스(회사 주식 및 옵션 포함). 는 $ 25.76K 가치에 해당하는 회사 주식의 0.19% 직접 소유합니다. 25.76K. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 4.4 년입니다.

주요 정보

Hans Schambye

최고 경영자

US$965.1k

총 보상

CEO 급여 비율	52.4%
CEO 임기	4.5yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	4.2yrs

최근 관리 업데이트

Recent updates

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Oct 19

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Oct 19

Galecto GAAP EPS of -$0.67 beats by $0.02

Jul 29

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Jun 30

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Mar 10

Galecto: Selling At Cash Value

Dec 19

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Nov 18

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Jul 07

Galecto EPS misses by $0.07

May 04

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Mar 23

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Jan 29

Galecto EPS misses by $41.65

Dec 11

CEO 보상 분석

Hans Schambye 의 보수는 Galecto 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$965k	US$506k	-US$38m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$58m
Dec 31 2022	US$1m	US$473k	-US$62m
Sep 30 2022	n/a	n/a	-US$61m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$3m	US$512k	-US$52m
Sep 30 2021	n/a	n/a	-US$42m
Jun 30 2021	n/a	n/a	-US$44m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$4m	US$387k	-US$35m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$48m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$479k	US$360k	-US$42m

보상 대 시장: Hans 의 총 보상 ($USD 965.12K )은 US 시장( $USD 683.56K ).

보상과 수익: Hans 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Hans Schambye (58 yo)

4.5yrs

테뉴어

US$965,115

보상

Dr. Hans T. Schambye, MD, Ph D, serves as Member of Board of Directors at BioInnovation Institute. Dr. Schambye is Co-Founder and has been Chief Executive Officer and Director at Galecto, Inc. since 2020 a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Hans Schambye	Co-Founder	4.5yrs	US$965.12k	0.19% $ 26.6k
Jonathan Freve	Chief Financial Officer	4.3yrs	US$701.33k	0.044% $ 6.1k
Garrett Winslow	Senior VP	3.2yrs	US$554.39k	0.015% $ 2.0k
Ulf Nilsson	Co-Founder	no data	데이터 없음	데이터 없음
Hakon Leffler	Co-Founder	no data	데이터 없음	데이터 없음
Tariq Sethi	Co-Founder	no data	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: GLTO 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hans Schambye	Co-Founder	4.5yrs	US$965.12k	0.19% $ 26.6k
Carl Goldfischer	Independent Chairman of the Board	4.5yrs	US$155.19k	0.035% $ 4.9k
David Shapiro	Independent Director	4.2yrs	US$148.84k	0% $ 0
Amit Munshi	Independent Director	4.2yrs	US$78.85k	0.018% $ 2.4k
Anne Prener	Independent Director	3.5yrs	US$83.85k	0% $ 0
Jayson Donald Dallas	Independent Director	3.7yrs	US$86.35k	0% $ 0
Jonathan Fallowfield	Member of Clinical Advisory Board – Liver cirrhosis	no data	데이터 없음	데이터 없음
Adam Mead	Member of the Clinical Advisory Board - Myelofibrosis	no data	데이터 없음	데이터 없음
Aaron Gerds	Member of the Clinical Advisory Board - Myelofibrosis	no data	데이터 없음	데이터 없음
Claire Harrison	Member of the Clinical Advisory Board - Myelofibrosis	no data	데이터 없음	데이터 없음
John Mascarenhas	Member of the Clinical Advisory Board - Myelofibrosis	no data	데이터 없음	데이터 없음
Raajit Rampal	Member of the Clinical Advisory Board - Myelofibrosis	no data	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: GLTO 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

Galecto 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Galecto, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

High number of new and inexperienced directors

High number of new directors

Galecto, Inc. Announces the Appointment of Dr. Anne Prener to Its Board of Directors

Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors

Recent updates

Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Galecto, Inc., Annual General Meeting, Jun 20, 2024

New major risk - Financial position

New minor risk - Share price stability

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Insufficient new directors

Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis

Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial

Galecto Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Financial position

Price target increased by 17% to US$12.00

Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely

Price target increased by 18% to US$10.25

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?

Price target decreased to US$8.33

High number of new and inexperienced directors

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022

Galecto, Inc’s Galectin-3 Inhibitor GB1211 to Be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc Announces Results from A Planned Intermediate Assessment of the Ongoing Phase 2A Trial of GB2064, a LOXL2 Inhibitor Product Candidate, for the Treatment of Myelofibrosis

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Price target decreased to US$10.00

Galecto GAAP EPS of -$0.67 beats by $0.02

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Enrolled in Phase 2 Trial of Gb1211 in Combination with Atezolizumab for First-Line Treatment of Nsclc

Price target decreased to US$11.00

High number of new directors

Galecto, Inc. Completes Enrollment in Global Phase 2B GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$9.50

Price target decreased to US$11.67

Galecto Publishes Results Showing Safety and Efficacy of the Gb0139 Inhaled Galectin-3 Inhibitor in Hospitalized Covid-19 Patients on Standard of Care

Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022

Galecto: Selling At Cash Value

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor Gb1211 in Liver Cirrhosis

Galecto, Inc. Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor Gb2064 in Myelofibrosis (The MYLOX-1 Trial)

Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc. Announces Preliminary Topline Results from Galectin-3 Inhibitor GB0139

Galecto EPS misses by $0.07

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Galecto, Inc. Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications

New 90-day low: US$11.99

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Galecto, Inc. Announces the Appointment of Dr. Anne Prener to Its Board of Directors

Galecto EPS misses by $41.65

Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors

Galecto, Inc. has completed an IPO in the amount of $85.000005 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령